A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3
Status:
Not yet recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
The main objective of this clinical trial represents the evaluation of efficacy of the
tyrosine kinase inhibitor Cabozantinib in patients with NEN G3 with a proliferation rate of
Ki67 20 - 60%.